Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

NCT00703664 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

NIH

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma
Recurrent Non-Hodgkin Lymphoma

Interventions

DRUG: Bortezomib
OTHER: Laboratory Biomarker Analysis
DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)